US HB8267 | 2023-2024 | 118th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on May 7 2024 - 25% progression
Action: 2024-05-07 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Status: Introduced on May 7 2024 - 25% progression
Action: 2024-05-07 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Summary
To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs, and for other purposes.
Title
To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs, and for other purposes.
Sponsors
| Rep. Donald Davis [D-NC] | Rep. August Pfluger [R-TX] |
History
| Date | Chamber | Action |
|---|---|---|
| 2024-05-07 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2024-05-07 | House | Introduced in House |
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/house-bill/8267/all-info |
